US life sciences company opens clinical trial bridge to India

Global Pharmaceutical Services Inc (GPSI), a US-based provider of clinical trial research and development support to the worldwide pharmaceutical and biotechnology industry announces a new clinical development bridge to India.

Located in Lawton, Michigan, GPSI entered into an exclusive partnership with Abridge Clinical Research Pvt Ltd, a research and development company located in Mumbai, India.

D. Emran Khan, director of Abridge, said: "India has become the hub of clinical research, as sponsors and Contract Research Organisations (CROs) from the USA can benefit from this relationship due to fast recruitment, good quality and cost effectiveness. In today's scenario of recession, India has become the favourite place for outsourcing the clinical studies. We are delighted to be working with GPSI in the offering of these services,"

This deal offers end-to-end services, including CRO selection for a specific clinical programme, monitoring of clinical studies, auditing, quality assurance, design and conduct of Phase I - IV clinical studies (including BA/BE, PK/PD, multiple dose, food effect and steady state), faster patient enrollment, in-country sponsor representative, medical writing (including protocols, investigator brochures, statistical reports, integrated clinical reports and abstracts), data management, biostatistical services, and regulatory support. Study status updates are available in real time for all clients.

GPSI will be the point of contact for US businesses who are interested in conducting clinical studies in India. Global Pharmaceutical Services Inc (GPSI), a US-based provider of clinical trial research and development support to the worldwide pharmaceutical and biotechnology industry announces a new clinical development bridge to India.

Located in Lawton, Michigan, GPSI entered into an exclusive partnership with Abridge Clinical Research Pvt Ltd, a research and development company located in Mumbai, India.

Dr. Emran Khan, Director of Abridge, said: "India has become the hub of clinical research, as sponsors and Contract Research Organisations (CROs) from the USA can benefit from this relationship due to fast recruitment, good quality and cost effectiveness. In today's scenario of recession, India has become the favourite place for outsourcing the clinical studies. We are delighted to be working with GPSI in the offering of these services,"

This deal offers end-to-end services, including CRO selection for a specific clinical programme, monitoring of clinical studies, auditing, quality assurance, design and conduct of Phase I - IV clinical studies (including BA/BE, PK/PD, multiple dose, food effect and steady state), faster patient enrollment, in-country sponsor representative, medical writing (including protocols, investigator brochures, statistical reports, integrated clinical reports and abstracts), data management, biostatistical services, and regulatory support. Study status updates are available in real time for all clients.

GPSI will be the point of contact for US businesses who are interested in conducting clinical studies in India.